High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Bhaskar C Kolla; Nurul A.A. Halim; Qing Cao; Zohar Sachs; Erica D Warlick; Daniel J Weisdorf; Aloysius Y.L. Ho; Wong G. Chuan; Zhentang Lao; Fiona He

doi:10.1111/bjh.17462

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Bhaskar C Kolla
, Nurul A.A. Halim
, Qing Cao
, Zohar Sachs
, Erica D Warlick
, Daniel J Weisdorf
, Aloysius Y.L. Ho
, Wong G. Chuan
, Zhentang Lao
, Fiona He

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m² q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m² q12h-D1,3,5/D1–3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40–82] compared with HIDAC (22%; 10–34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.

Original language	English (US)
Pages (from-to)	140-144
Number of pages	5
Journal	British journal of haematology
Volume	194
Issue number	1
Early online date	Apr 11 2021
DOIs	https://doi.org/10.1111/bjh.17462
State	Published - Jul 2021

Bibliographical note

Funding Information:
None of the authors received funding support for the conduct of this study. Support received outside of this study: DW received research support from FATE therapeutics and Incyte; ZL received NMRC research training fellowship, speaker fees from Astellas and Amgen, honoraria from Astellas, Amgen and Novartis; ZS received research reagents from Jazz pharmaceuticals, research funds and reagents from Stemline therapeutics; FH received consultant fees from Abbvie and Magenta therapeutics.

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

acute leukaemia
chemotherapy
consolidation

PubMed: MeSH publication types

Journal Article
Comparative Study
Multicenter Study
Review

Publisher link

10.1111/bjh.17462

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature'. Together they form a unique fingerprint.

Cite this

Kolla, B. C., Halim, N. A. A., Cao, Q., Sachs, Z., Warlick, E. D., Weisdorf, D. J., Ho, A. Y. L., Chuan, W. G., Lao, Z., & He, F. (2021). High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. British journal of haematology, 194(1), 140-144. https://doi.org/10.1111/bjh.17462

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. / Kolla, Bhaskar C; Halim, Nurul A.A.; Cao, Qing et al.
In: British journal of haematology, Vol. 194, No. 1, 07.2021, p. 140-144.

Research output: Contribution to journal › Article › peer-review

Kolla, BC, Halim, NAA, Cao, Q , Sachs, Z, Warlick, ED, Weisdorf, DJ, Ho, AYL, Chuan, WG, Lao, Z & He, F 2021, 'High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature', British journal of haematology, vol. 194, no. 1, pp. 140-144. https://doi.org/10.1111/bjh.17462

Kolla BC, Halim NAA, Cao Q , Sachs Z, Warlick ED, Weisdorf DJ et al. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. British journal of haematology. 2021 Jul;194(1):140-144. Epub 2021 Apr 11. doi: 10.1111/bjh.17462

@article{f46f07008fd24797bf2b9082b7d9a799,

title = "High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature",

abstract = "Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m2 q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m2 q12h-D1,3,5/D1{\textendash}3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61\%; 95\% confidence interval (CI) 40{\textendash}82] compared with HIDAC (22\%; 10{\textendash}34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.",

keywords = "acute leukaemia, chemotherapy, consolidation",

author = "Kolla, \{Bhaskar C\} and Halim, \{Nurul A.A.\} and Qing Cao and Zohar Sachs and Warlick, \{Erica D\} and Weisdorf, \{Daniel J\} and Ho, \{Aloysius Y.L.\} and Chuan, \{Wong G.\} and Zhentang Lao and Fiona He",

note = "Funding Information: None of the authors received funding support for the conduct of this study. Support received outside of this study: DW received research support from FATE therapeutics and Incyte; ZL received NMRC research training fellowship, speaker fees from Astellas and Amgen, honoraria from Astellas, Amgen and Novartis; ZS received research reagents from Jazz pharmaceuticals, research funds and reagents from Stemline therapeutics; FH received consultant fees from Abbvie and Magenta therapeutics. Publisher Copyright: {\textcopyright} 2021 British Society for Haematology and John Wiley \& Sons Ltd",

year = "2021",

month = jul,

doi = "10.1111/bjh.17462",

language = "English (US)",

volume = "194",

pages = "140--144",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3

T2 - a retrospective multicentre analysis and critical review of the literature

AU - Kolla, Bhaskar C

AU - Halim, Nurul A.A.

AU - Cao, Qing

AU - Sachs, Zohar

AU - Warlick, Erica D

AU - Weisdorf, Daniel J

AU - Ho, Aloysius Y.L.

AU - Chuan, Wong G.

AU - Lao, Zhentang

AU - He, Fiona

N1 - Funding Information: None of the authors received funding support for the conduct of this study. Support received outside of this study: DW received research support from FATE therapeutics and Incyte; ZL received NMRC research training fellowship, speaker fees from Astellas and Amgen, honoraria from Astellas, Amgen and Novartis; ZS received research reagents from Jazz pharmaceuticals, research funds and reagents from Stemline therapeutics; FH received consultant fees from Abbvie and Magenta therapeutics. Publisher Copyright: © 2021 British Society for Haematology and John Wiley & Sons Ltd

PY - 2021/7

Y1 - 2021/7

N2 - Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m2 q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m2 q12h-D1,3,5/D1–3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40–82] compared with HIDAC (22%; 10–34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.

AB - Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m2 q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m2 q12h-D1,3,5/D1–3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40–82] compared with HIDAC (22%; 10–34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.

KW - acute leukaemia

KW - chemotherapy

KW - consolidation

UR - https://www.scopus.com/pages/publications/85104156479

UR - https://www.scopus.com/pages/publications/85104156479#tab=citedBy

U2 - 10.1111/bjh.17462

DO - 10.1111/bjh.17462

M3 - Article

C2 - 33843048

SN - 0007-1048

VL - 194

SP - 140

EP - 144

JO - British journal of haematology

JF - British journal of haematology

IS - 1

ER -

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Abstract

Bibliographical note

UN SDGs

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this